<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d480" origId="Paclitaxel"><sentence id="DrugDDI.d480.s0" origId="s0" text="In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin)."><entity id="DrugDDI.d480.s0.e0" origId="s0.p3" charOffset="45-50" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s0.e1" origId="s0.p9" charOffset="71-80" type="drug" text="cisplatin"/><entity id="DrugDDI.d480.s0.e2" origId="s0.p22" charOffset="169-174" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s0.e3" origId="s0.p25" charOffset="191-200" type="drug" text="cisplatin"/><entity id="DrugDDI.d480.s0.e4" origId="s0.p30" charOffset="239-244" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s0.e5" origId="s0.p31" charOffset="252-261" type="drug" text="cisplatin"/><pair id="DrugDDI.d480.s0.p0" e1="DrugDDI.d480.s0.e0" e2="DrugDDI.d480.s0.e1" interaction="?"/><pair id="DrugDDI.d480.s0.p1" e1="DrugDDI.d480.s0.e0" e2="DrugDDI.d480.s0.e2" interaction="?"/><pair id="DrugDDI.d480.s0.p2" e1="DrugDDI.d480.s0.e0" e2="DrugDDI.d480.s0.e3" interaction="?"/><pair id="DrugDDI.d480.s0.p3" e1="DrugDDI.d480.s0.e0" e2="DrugDDI.d480.s0.e4" interaction="?"/><pair id="DrugDDI.d480.s0.p4" e1="DrugDDI.d480.s0.e0" e2="DrugDDI.d480.s0.e5" interaction="?"/><pair id="DrugDDI.d480.s0.p5" e1="DrugDDI.d480.s0.e1" e2="DrugDDI.d480.s0.e2" interaction="?"/><pair id="DrugDDI.d480.s0.p6" e1="DrugDDI.d480.s0.e1" e2="DrugDDI.d480.s0.e3" interaction="?"/><pair id="DrugDDI.d480.s0.p7" e1="DrugDDI.d480.s0.e1" e2="DrugDDI.d480.s0.e4" interaction="?"/><pair id="DrugDDI.d480.s0.p8" e1="DrugDDI.d480.s0.e1" e2="DrugDDI.d480.s0.e5" interaction="?"/><pair id="DrugDDI.d480.s0.p9" e1="DrugDDI.d480.s0.e2" e2="DrugDDI.d480.s0.e3" interaction="?"/><pair id="DrugDDI.d480.s0.p10" e1="DrugDDI.d480.s0.e2" e2="DrugDDI.d480.s0.e4" interaction="?"/><pair id="DrugDDI.d480.s0.p11" e1="DrugDDI.d480.s0.e2" e2="DrugDDI.d480.s0.e5" interaction="?"/><pair id="DrugDDI.d480.s0.p12" e1="DrugDDI.d480.s0.e3" e2="DrugDDI.d480.s0.e4" interaction="?"/><pair id="DrugDDI.d480.s0.p13" e1="DrugDDI.d480.s0.e3" e2="DrugDDI.d480.s0.e5" interaction="?"/><pair id="DrugDDI.d480.s0.p14" e1="DrugDDI.d480.s0.e4" e2="DrugDDI.d480.s0.e5" interaction="?"/></sentence><sentence id="DrugDDI.d480.s1" origId="s1" text="Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin."><entity id="DrugDDI.d480.s1.e0" origId="s1.p37" charOffset="68-78" type="drug" text="paclitaxel"/><entity id="DrugDDI.d480.s1.e1" origId="s1.p40" charOffset="115-120" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s1.e2" origId="s1.p44" charOffset="148-157" type="drug" text="cisplatin"/><pair id="DrugDDI.d480.s1.p0" e1="DrugDDI.d480.s1.e0" e2="DrugDDI.d480.s1.e1" interaction="?"/><pair id="DrugDDI.d480.s1.p1" e1="DrugDDI.d480.s1.e0" e2="DrugDDI.d480.s1.e2" interaction="?"/><pair id="DrugDDI.d480.s1.p2" e1="DrugDDI.d480.s1.e1" e2="DrugDDI.d480.s1.e2" interaction="?"/></sentence><sentence id="DrugDDI.d480.s2" origId="s2" text="The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4."><entity id="DrugDDI.d480.s2.e0" origId="s2.p46" charOffset="18-23" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s2.e1" origId="s2.p49" charOffset="40-55" type="drug" text="cytochrome P450"/><entity id="DrugDDI.d480.s2.e2" origId="s2.p51" charOffset="79-85" type="drug" text="CYP3A4"/><pair id="DrugDDI.d480.s2.p0" e1="DrugDDI.d480.s2.e0" e2="DrugDDI.d480.s2.e1" interaction="?"/><pair id="DrugDDI.d480.s2.p1" e1="DrugDDI.d480.s2.e0" e2="DrugDDI.d480.s2.e2" interaction="?"/><pair id="DrugDDI.d480.s2.p2" e1="DrugDDI.d480.s2.e1" e2="DrugDDI.d480.s2.e2" interaction="?"/></sentence><sentence id="DrugDDI.d480.s3" origId="s3" text="In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4."><entity id="DrugDDI.d480.s3.e0" origId="s3.p59" charOffset="107-112" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s3.e1" origId="s3.p63" charOffset="170-185" type="drug" text="cytochrome P450"/><entity id="DrugDDI.d480.s3.e2" origId="s3.p65" charOffset="208-214" type="drug" text="CYP3A4"/><pair id="DrugDDI.d480.s3.p0" e1="DrugDDI.d480.s3.e0" e2="DrugDDI.d480.s3.e1" interaction="?"/><pair id="DrugDDI.d480.s3.p1" e1="DrugDDI.d480.s3.e0" e2="DrugDDI.d480.s3.e2" interaction="?"/><pair id="DrugDDI.d480.s3.p2" e1="DrugDDI.d480.s3.e1" e2="DrugDDI.d480.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d480.s4" origId="s4" text="Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."><entity id="DrugDDI.d480.s4.e0" origId="s4.p67" charOffset="31-36" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s4.e1" origId="s4.p69" charOffset="53-59" type="drug" text="CYP3A4"/><entity id="DrugDDI.d480.s4.e2" origId="s4.p71" charOffset="65-84" type="drug" text="protease inhibitors"/><entity id="DrugDDI.d480.s4.e3" origId="s4.p73" charOffset="86-95" type="drug" text="ritonavir"/><entity id="DrugDDI.d480.s4.e4" origId="s4.p74" charOffset="97-107" type="drug" text="saquinavir"/><entity id="DrugDDI.d480.s4.e5" origId="s4.p75" charOffset="109-118" type="drug" text="indinavir"/><entity id="DrugDDI.d480.s4.e6" origId="s4.p77" charOffset="124-134" type="drug" text="nelfinavir"/><entity id="DrugDDI.d480.s4.e7" origId="s4.p85" charOffset="179-185" type="drug" text="CYP3A4"/><pair id="DrugDDI.d480.s4.p0" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e1" interaction="?"/><pair id="DrugDDI.d480.s4.p1" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e2" interaction="?"/><pair id="DrugDDI.d480.s4.p2" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e3" interaction="?"/><pair id="DrugDDI.d480.s4.p3" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e4" interaction="?"/><pair id="DrugDDI.d480.s4.p4" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e5" interaction="?"/><pair id="DrugDDI.d480.s4.p5" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p6" e1="DrugDDI.d480.s4.e0" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p7" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e2" interaction="?"/><pair id="DrugDDI.d480.s4.p8" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e3" interaction="?"/><pair id="DrugDDI.d480.s4.p9" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e4" interaction="?"/><pair id="DrugDDI.d480.s4.p10" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e5" interaction="?"/><pair id="DrugDDI.d480.s4.p11" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p12" e1="DrugDDI.d480.s4.e1" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p13" e1="DrugDDI.d480.s4.e2" e2="DrugDDI.d480.s4.e3" interaction="?"/><pair id="DrugDDI.d480.s4.p14" e1="DrugDDI.d480.s4.e2" e2="DrugDDI.d480.s4.e4" interaction="?"/><pair id="DrugDDI.d480.s4.p15" e1="DrugDDI.d480.s4.e2" e2="DrugDDI.d480.s4.e5" interaction="?"/><pair id="DrugDDI.d480.s4.p16" e1="DrugDDI.d480.s4.e2" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p17" e1="DrugDDI.d480.s4.e2" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p18" e1="DrugDDI.d480.s4.e3" e2="DrugDDI.d480.s4.e4" interaction="?"/><pair id="DrugDDI.d480.s4.p19" e1="DrugDDI.d480.s4.e3" e2="DrugDDI.d480.s4.e5" interaction="?"/><pair id="DrugDDI.d480.s4.p20" e1="DrugDDI.d480.s4.e3" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p21" e1="DrugDDI.d480.s4.e3" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p22" e1="DrugDDI.d480.s4.e4" e2="DrugDDI.d480.s4.e5" interaction="?"/><pair id="DrugDDI.d480.s4.p23" e1="DrugDDI.d480.s4.e4" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p24" e1="DrugDDI.d480.s4.e4" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p25" e1="DrugDDI.d480.s4.e5" e2="DrugDDI.d480.s4.e6" interaction="?"/><pair id="DrugDDI.d480.s4.p26" e1="DrugDDI.d480.s4.e5" e2="DrugDDI.d480.s4.e7" interaction="?"/><pair id="DrugDDI.d480.s4.p27" e1="DrugDDI.d480.s4.e6" e2="DrugDDI.d480.s4.e7" interaction="?"/></sentence><sentence id="DrugDDI.d480.s5" origId="s5" text="Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination."><entity id="DrugDDI.d480.s5.e0" origId="s5.p95" charOffset="56-67" type="drug" text="doxorubicin"/><entity id="DrugDDI.d480.s5.e1" origId="s5.p98" charOffset="77-94" type="drug" text="active metabolite"/><entity id="DrugDDI.d480.s5.e2" origId="s5.p104" charOffset="132-142" type="drug" text="paclitaxel"/><entity id="DrugDDI.d480.s5.e3" origId="s5.p106" charOffset="147-158" type="drug" text="doxorubicin"/><pair id="DrugDDI.d480.s5.p0" e1="DrugDDI.d480.s5.e0" e2="DrugDDI.d480.s5.e1" interaction="?"/><pair id="DrugDDI.d480.s5.p1" e1="DrugDDI.d480.s5.e0" e2="DrugDDI.d480.s5.e2" interaction="?"/><pair id="DrugDDI.d480.s5.p2" e1="DrugDDI.d480.s5.e0" e2="DrugDDI.d480.s5.e3" interaction="?"/><pair id="DrugDDI.d480.s5.p3" e1="DrugDDI.d480.s5.e1" e2="DrugDDI.d480.s5.e2" interaction="?"/><pair id="DrugDDI.d480.s5.p4" e1="DrugDDI.d480.s5.e1" e2="DrugDDI.d480.s5.e3" interaction="?"/><pair id="DrugDDI.d480.s5.p5" e1="DrugDDI.d480.s5.e2" e2="DrugDDI.d480.s5.e3" interaction="?"/></sentence><sentence id="DrugDDI.d480.s6" origId="s6" text="Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3."><entity id="DrugDDI.d480.s6.e0" origId="s6.p112" charOffset="12-17" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s7" origId="s7" text="In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL."><entity id="DrugDDI.d480.s7.e0" origId="s7.p135" charOffset="153-158" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s8" origId="s8" text="Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3."><entity id="DrugDDI.d480.s8.e0" origId="s8.p142" charOffset="60-65" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s9" origId="s9" text="In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended."><entity id="DrugDDI.d480.s9.e0" origId="s9.p162" charOffset="93-98" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s10" origId="s10" text="For patients with advanced HIV disease and poor-risk AIDS-related Kaposi?s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3."><entity id="DrugDDI.d480.s10.e0" origId="s10.p170" charOffset="27-30" type="drug" text="HIV"/><entity id="DrugDDI.d480.s10.e1" origId="s10.p173" charOffset="84-89" type="drug" text="TAXOL"/><pair id="DrugDDI.d480.s10.p0" e1="DrugDDI.d480.s10.e0" e2="DrugDDI.d480.s10.e1" interaction="?"/></sentence><sentence id="DrugDDI.d480.s11" origId="s11" text="Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor? EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL."><entity id="DrugDDI.d480.s11.e0" origId="s11.p198" charOffset="131-142" type="drug" text="cyclosporin"/><entity id="DrugDDI.d480.s11.e1" origId="s11.p201" charOffset="173-183" type="drug" text="teniposide"/><entity id="DrugDDI.d480.s11.e2" origId="s11.p208" charOffset="238-243" type="drug" text="TAXOL"/><pair id="DrugDDI.d480.s11.p0" e1="DrugDDI.d480.s11.e0" e2="DrugDDI.d480.s11.e1" interaction="?"/><pair id="DrugDDI.d480.s11.p1" e1="DrugDDI.d480.s11.e0" e2="DrugDDI.d480.s11.e2" interaction="?"/><pair id="DrugDDI.d480.s11.p2" e1="DrugDDI.d480.s11.e1" e2="DrugDDI.d480.s11.e2" interaction="?"/></sentence><sentence id="DrugDDI.d480.s12" origId="s12" text="In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine)."><entity id="DrugDDI.d480.s12.e0" origId="s12.p215" charOffset="97-102" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s12.e1" origId="s12.p219" charOffset="131-146" type="drug" text="corticosteroids"/><entity id="DrugDDI.d480.s12.e2" origId="s12.p221" charOffset="156-169" type="drug" text="dexamethasone"/><entity id="DrugDDI.d480.s12.e3" origId="s12.p224" charOffset="172-178" type="drug" text="diphen"/><entity id="DrugDDI.d480.s12.e4" origId="s12.p228" charOffset="217-227" type="drug" text="cimetidine"/><entity id="DrugDDI.d480.s12.e5" origId="s12.p230" charOffset="231-241" type="drug" text="ranitidine"/><pair id="DrugDDI.d480.s12.p0" e1="DrugDDI.d480.s12.e0" e2="DrugDDI.d480.s12.e1" interaction="?"/><pair id="DrugDDI.d480.s12.p1" e1="DrugDDI.d480.s12.e0" e2="DrugDDI.d480.s12.e2" interaction="?"/><pair id="DrugDDI.d480.s12.p2" e1="DrugDDI.d480.s12.e0" e2="DrugDDI.d480.s12.e3" interaction="?"/><pair id="DrugDDI.d480.s12.p3" e1="DrugDDI.d480.s12.e0" e2="DrugDDI.d480.s12.e4" interaction="?"/><pair id="DrugDDI.d480.s12.p4" e1="DrugDDI.d480.s12.e0" e2="DrugDDI.d480.s12.e5" interaction="?"/><pair id="DrugDDI.d480.s12.p5" e1="DrugDDI.d480.s12.e1" e2="DrugDDI.d480.s12.e2" interaction="?"/><pair id="DrugDDI.d480.s12.p6" e1="DrugDDI.d480.s12.e1" e2="DrugDDI.d480.s12.e3" interaction="?"/><pair id="DrugDDI.d480.s12.p7" e1="DrugDDI.d480.s12.e1" e2="DrugDDI.d480.s12.e4" interaction="?"/><pair id="DrugDDI.d480.s12.p8" e1="DrugDDI.d480.s12.e1" e2="DrugDDI.d480.s12.e5" interaction="?"/><pair id="DrugDDI.d480.s12.p9" e1="DrugDDI.d480.s12.e2" e2="DrugDDI.d480.s12.e3" interaction="?"/><pair id="DrugDDI.d480.s12.p10" e1="DrugDDI.d480.s12.e2" e2="DrugDDI.d480.s12.e4" interaction="?"/><pair id="DrugDDI.d480.s12.p11" e1="DrugDDI.d480.s12.e2" e2="DrugDDI.d480.s12.e5" interaction="?"/><pair id="DrugDDI.d480.s12.p12" e1="DrugDDI.d480.s12.e3" e2="DrugDDI.d480.s12.e4" interaction="?"/><pair id="DrugDDI.d480.s12.p13" e1="DrugDDI.d480.s12.e3" e2="DrugDDI.d480.s12.e5" interaction="?"/><pair id="DrugDDI.d480.s12.p14" e1="DrugDDI.d480.s12.e4" e2="DrugDDI.d480.s12.e5" interaction="?"/></sentence><sentence id="DrugDDI.d480.s13" origId="s13" text="Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy."/><sentence id="DrugDDI.d480.s14" origId="s14" text="However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy."><entity id="DrugDDI.d480.s14.e0" origId="s14.p247" charOffset="86-101" type="drug" text="bronchodilators"/><entity id="DrugDDI.d480.s14.e1" origId="s14.p253" charOffset="177-182" type="drug" text="TAXOL"/><pair id="DrugDDI.d480.s14.p0" e1="DrugDDI.d480.s14.e0" e2="DrugDDI.d480.s14.e1" interaction="?"/></sentence><sentence id="DrugDDI.d480.s15" origId="s15" text="Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL."><entity id="DrugDDI.d480.s15.e0" origId="s15.p265" charOffset="94-99" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s16" origId="s16" text="Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment."><entity id="DrugDDI.d480.s16.e0" origId="s16.p276" charOffset="103-108" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s17" origId="s17" text="Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension."><entity id="DrugDDI.d480.s17.e0" origId="s17.p283" charOffset="13-18" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s18" origId="s18" text="Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended."><entity id="DrugDDI.d480.s18.e0" origId="s18.p295" charOffset="70-75" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s19" origId="s19" text="Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities."/><sentence id="DrugDDI.d480.s20" origId="s20" text="Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL."><entity id="DrugDDI.d480.s20.e0" origId="s20.p320" charOffset="196-201" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s21" origId="s21" text="TAXOL contains dehydrated alcohol USP, 396 mg/mL;"><entity id="DrugDDI.d480.s21.e0" origId="s21.p321" charOffset="0-5" type="drug" text="TAXOL"/><entity id="DrugDDI.d480.s21.e1" origId="s21.p323" charOffset="15-38" type="drug" text="dehydrated alcohol USP"/><pair id="DrugDDI.d480.s21.p0" e1="DrugDDI.d480.s21.e0" e2="DrugDDI.d480.s21.e1" interaction="?"/></sentence><sentence id="DrugDDI.d480.s22" origId="s22" text="consideration should be given to possible CNS and other effects of alcohol."><entity id="DrugDDI.d480.s22.e0" origId="s22.p334" charOffset="67-74" type="drug" text="alcohol"/></sentence><sentence id="DrugDDI.d480.s23" origId="s23" text="Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN."><entity id="DrugDDI.d480.s23.e0" origId="s23.p342" charOffset="61-66" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s24" origId="s24" text="Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17."><entity id="DrugDDI.d480.s24.e0" origId="s24.p354" charOffset="55-60" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s25" origId="s25" text="InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site."/><sentence id="DrugDDI.d480.s26" origId="s26" text="These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion."/><sentence id="DrugDDI.d480.s27" origId="s27" text="Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely."><entity id="DrugDDI.d480.s27.e0" origId="s27.p393" charOffset="93-98" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s28" origId="s28" text="Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety."><entity id="DrugDDI.d480.s28.e0" origId="s28.p417" charOffset="180-185" type="drug" text="TAXOL"/></sentence><sentence id="DrugDDI.d480.s29" origId="s29" text="In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days."/><sentence id="DrugDDI.d480.s30" origId="s30" text="A specific treatment for extravasation reactions is unknown at this time."/><sentence id="DrugDDI.d480.s31" origId="s31" text="Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration."/></document>